Alixorexton is named as an intervention in 3 current clinical trials in our USA, Canada, France, Spain, Italy, Netherlands, Belgium, Japan, Australia and Poland registers. 3 are recruiting patients now. All registered phases are Phase 3. The lead sponsor is Alkermes, Inc. The most-studied condition is Narcolepsy Type 1.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
NCT07455383 · ClinicalTrials.gov ↗ · Narcolepsy Type 1
|
Phase 3 | Recruiting | Alkermes, Inc | USA, France, Spain, Italy, Netherlands, Belgium, Canada, Japan, Australia |
|
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
NCT07502443 · Narcolepsy Type 2
|
Phase 3 | Recruiting | Alkermes, Inc | USA, France, Spain, Italy, Netherlands, Belgium, Canada, Japan, Australia |
|
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
NCT07540897 · ClinicalTrials.gov ↗ · Narcolepsy Type 1
|
Phase 3 | Recruiting | Alkermes, Inc | USA, Poland, Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Alkermes, Inc | 3 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA, Canada, France, Spain, Italy, Netherlands, Belgium, Japan, Australia and Poland registers name Alixorexton (also registered as ALKS 2680 1) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 3 with sites in USA, 3 with sites in Canada, 2 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Netherlands, 2 with sites in Belgium, 2 with sites in Japan, 2 with sites in Australia and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Alkermes, Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Alixorexton works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Alixorexton works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Alixorexton (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.